Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0H9HT
|
|||
| Former ID |
DCL000656
|
|||
| Drug Name |
TAK-701
|
|||
| Synonyms |
SCHEMBL131582
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Advanced malignancy [ICD-11: 2A00-2F9Z; ICD-10: C00-C96; ICD-9: 140-229] | Phase 1 | [1] | |
| Company |
Takeda
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C18H16N6S2
|
|||
| Canonical SMILES |
[C-]#[N+]C(=C(N)SC1=CC=CC=C1N)C(=C(N)SC2=CC=CC=C2N)C#N
|
|||
| InChI |
1S/C18H16N6S2/c1-24-16(18(23)26-15-9-5-3-7-13(15)21)11(10-19)17(22)25-14-8-4-2-6-12(14)20/h2-9H,20-23H2/b17-11+,18-16-
|
|||
| InChIKey |
OSXOBXXOVNWNOP-UNEKJRSWSA-N
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00831896) Phase I Study of TAK-701 in Adult Patients With Advanced Nonhematological Malignancies. U.S. National Institutes of Health. | |||
| REF 2 | Targeting MET in cancer: rationale and progress.Nat Rev Cancer.2012 Jan 24;12(2):89-103. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.